Suppr超能文献

口服伤寒活疫苗伤寒沙门氏菌 Ty21a- 一种针对非伤寒沙门氏菌的替代疫苗?

Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?

机构信息

Department of Medicine, Division of Infectious Diseases, 00029 Helsinki University Hospital, Helsinki, Finland.

出版信息

Vaccine. 2012 Nov 26;30(50):7238-45. doi: 10.1016/j.vaccine.2012.10.002. Epub 2012 Oct 17.

Abstract

BACKGROUND

Non-typhoid Salmonella (NTS) is a leading cause of food-borne illness with more than 90 million annual cases and an emerging antimicrobial resistance among the strains worldwide. Paradoxically, no vaccines are available against these pathogens. Numerous NTS strains share surface O-antigens with Salmonella enterica serotype Typhi. As intestinal antibodies against O-antigens have proven protective against NTS in animal experiments, it appears conceivable that the oral whole-cell typhoid vaccine, Salmonella Typhi Ty21a (Vivotif(®)), which effectively elicits intestinal antibodies against O-antigens, could exhibit cross-protective efficacy against NTS. We sought immunological evidence in support of cross-protective efficacy of Ty21a against NTS.

MATERIALS AND METHODS

35 volunteers receiving Ty21a vaccine and five patients with enteric fever were investigated with ELISPOT for circulating plasmablasts secreting antibodies reactive with Salmonella Typhi and six different NTS serotypes. These plasmablasts were also analysed for homing receptor expressions.

RESULTS

In all vaccinees and patients, a strong gut-directed cross-reactive plasmablast response was found against serotypes sharing the two O-antigens with Salmonella Typhi (O-9,12) (in vaccinees, mean: 95%CI 268: 228-508 and 363: 234-493 plasmablasts/10(6)PBMC against Salmonella Typhi and Enteritidis). Responses against strains sharing one O-antigen (O-12) were weaker (222: 105-338 against Salmonella Typhimurium), while no significant reactivity was detected against strains without typhoidal O-antigens.

CONCLUSIONS

Intestinal antibodies against O-antigens protect against NTS in animal experiments. Ty21a was found to elicit intestinal immune responses cross-reactive with NTS strains sharing O-antigens with Ty21a. These include the most common NTS, Salmonella Enteritidis and Typhimurium. The data suggest that Ty21a may have cross-protective efficacy against numerous NTS strains.

摘要

背景

非伤寒沙门氏菌(NTS)是食源性疾病的主要原因,全球每年有超过 9000 万例病例,且菌株的抗药性不断出现。矛盾的是,目前尚无针对这些病原体的疫苗。许多 NTS 菌株与肠炎沙门氏菌血清型 Typhi 共享表面 O-抗原。由于肠道针对 O-抗原的抗体已被证明在动物实验中对 NTS 具有保护作用,因此口服全细胞伤寒疫苗沙门氏菌 Typhi Ty21a(Vivotif(®))似乎可以有效地诱导针对 O-抗原的肠道抗体,从而对 NTS 产生交叉保护作用。我们寻求免疫方面的证据来支持 Ty21a 对 NTS 的交叉保护作用。

材料和方法

对 35 名接受 Ty21a 疫苗接种的志愿者和 5 名肠热病患者进行了 ELISPOT 检测,以检测针对沙门氏菌 Typhi 和 6 种不同 NTS 血清型的循环浆母细胞分泌的抗体。还分析了这些浆母细胞的归巢受体表达。

结果

在所有疫苗接种者和患者中,均发现针对与沙门氏菌 Typhi 共享两种 O-抗原(O-9,12)的血清型存在强烈的肠道交叉反应性浆母细胞反应(在疫苗接种者中,平均:95%CI 268:228-508 和 363:234-493 个浆母细胞/10(6)PBMC 针对沙门氏菌 Typhi 和肠炎沙门氏菌)。针对仅共享一种 O-抗原(O-12)的菌株的反应较弱(针对鼠伤寒沙门氏菌 222:105-338),而对没有伤寒 O-抗原的菌株则未检测到明显的反应性。

结论

肠道针对 O-抗原的抗体可在动物实验中预防 NTS。Ty21a 被发现可诱导与 Ty21a 共享 O-抗原的 NTS 菌株发生交叉反应性的肠道免疫反应。这些包括最常见的 NTS,肠炎沙门氏菌和鼠伤寒沙门氏菌。数据表明,Ty21a 可能对许多 NTS 菌株具有交叉保护作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验